Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung

Lung Cancer

Volumn 27, Issue 1, 2000, Pages 37-45

  Schilder, Russell J ^a   Goldberg, Melvyn ^a   Millenson, Michael M ^a   Movsas, Benjamin ^a   Rogatko, André ^a   Rogers, Barbara ^a   Langer, Corey J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

High dose chemotherapy; Lung cancer; Neoadjuvant; Peripheral blood stem cells

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIMODALITY CANCER THERAPY; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOTHERAPY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PACLITAXEL; THORACOTOMY; TREATMENT OUTCOME;

EID: 0033990661     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(99)00091-4     Document Type: Article

References (49)

1. Cox J.D., Komabi R., Byhardt R.W. Is immediate chest radiotherapy obligatory for any or all patients with limited-stage non-small cell carcinoma of the lung? Cancer Treat. Rep. 67:1983;327-331.
2. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J. Clin. Oncol. 15(8):1997;2996-3018.
3. Bonomi P. Brief overview of combination chemotherapy in non-small cell lung cancer. Semin. Oncol. 13:1986;89-94.
4. Gralla R.J. New directions in non-small-cell lung cancer. Semin. Oncol. 17(Suppl. 7):1990;14-19.
5. Green M.R. Sequential chemotherapy and radiotherapy for initial management of stage IIIa and Stage IIIb non-small cell lung cancer-induction chemotherapy. Lung Cancer. 7:1991;77-84.
6. Johnson D.H. Chemotherapy for unresectable non-small cell lung cancer. Semin. Oncol. 17(Suppl. 7):1990;20-29.
7. Shephard F.A. Induction chemotherapy for locally advanced non-small cell lung cancer. Ann. Thor. Surg. 55:1993;1585-1592.
8. Bonomi P.D., Finkelstein D.M., Ruckdeschel J.C. et al. Combination chemotherapy versus single agents followed by combination chemotherapy in Stage IV non-small-cell lung cancer: A Study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 7:1989;1602-1613.
9. Klastersky J., Sculier J.P., La Croix H. et al. A randomized study comparing cisplatin or carboplatin with patients with advanced non-small cell lung cancer: Europe Organization for Research and Treatment of Cancer Protocol 07861. J. Clin. Oncol. 8:1990;1556-1562.
10. Chang A.Y., Kim K., Glick J. et al. Phase II study of Taxol, Merbarone, and Piroxantrone in Stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J. Natl. Cancer Inst. 85:1993;388-394.
11. Murphy W.K., Fossella F.V., Winn R.J. et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 85(5):1993;384.
12. Johnson D.H., Paul D.M., Hande K.R. et al. Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A phase II trial. J. Clin. Oncol. 14:1996;2054-2060.
13. Langer C.J., Leighton J.C., Comis R.L. et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity, response, and survival analysis. J. Clin. Oncol. 13:1995;1860-1870.
14. Belani C.P., Natale R.B., Lee J.S. et al. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 17:1998;455a.
15. Kelly K., Crowley J., Bunn P.A. et al. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC): A Southwest Oncology Group (SWOG) trial. Proc. Am. Soc. Clin. Oncol. 18:1999;461a.
16. Shea T.C., Flaherty M., Elias A. et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J. Clin. Oncol. 7:1989;651-661.
17. Shea T.C., Mason J.R., Storniolo A.M. et al. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: A novel and effective method for delivering multiple courses of dose-intensive therapy. J. Clin. Oncol. 10:1992;464-473.
18. Crown J., Kritz A., Vahdat L. et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J. Clin. Oncol. 11:1993;1144-1149.
19. Crown J., Wassherheit C., Hakes T. et al. Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. J. Natl. Cancer Inst. 84:1992;1935-1936.
20. Tepler I., Cannistra S.A., Frei E. et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy. J. Clin. Oncol. 11:1993;1583-1591.
21. Schilder R.J., Johnson S., Gallo J. et al. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. J. Clin. Oncol. 17:1999;2198-2207.
22. Gianni A.M., Gregni M., Siena S. et al. Granulocyte-macrophage colony-stimulating factor or granulocyte colony-stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and myeloma patients. J. Clin. Oncol. 10:1992;1955-1962.
23. Cockroft D.W., Gault M.H. Prediction of creatinine clearance from a serum creatinine. Nephron. 16:1976;31-36.
24. Calvert A.H., Newell D.R., Gumbrell L.A. et al. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7:1989;1748-1756.
25. Mountain C.F. Prognostic implications of the international staging system for lung cancer. Semin. Oncol. 3:1988;236-245.
26. Martini N., Flehinger B.J. The role of surgery in N2 lung cancer. Surg. Clin. North Am. 67:1987;1037-1049.
27. Thomas P.A., Piantadosi S., Mountain C.F. Should subcarinal lymph nodes be routinely examined in patients with non-small cell lung cancer? J. Thor. Cardiovasc. Surg. 95:1988;883-887.
28. Naruke T., Suamasu K., Ishikawa S. et al. Mediastinal lymph node dissection and its significance in surgery of lung cancer. Lung Cancer. 2:1986;96.
29. Minna J.D., Pass H., Glatstein I. et al. Cancer of the lung. DeVita V.T., Hellman S., Rosenberg S.A. Cancer: Principles and Practice of Oncology. 3rd ed. 1989;647 J.B. Lippincott Co, Philadelphia.
30. Dillman R.O., Herndon J., Seagren et al. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia groups B (CALGB) 8433 trial. J. Natl. Cancer Inst. 88(17):1996;1210-1215.
31. Albain K.S., Rusch V.W., Crowley J.J. et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group Phase II study 8805. J. Clin. Oncol. 13:1995;1880-1892.
32. Martini N., Kris M.G., Flehinger B.J. et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: The Sloan-Kettering Experience with 136 patients. Am. Thor. Surg. 55:1993;1365-1374.
33. Lad T., Wagner H., Piantadose S. Randomized phase II evaluation of pre-operative chemotherapy alone and radiotherapy alone in stage IIIa non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 10:1991;258. abstract.
34. Burkes R.L., Ginsberg R.J., Shepherd F.A. et al. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small cell lung cancer: Results of the Toronto Phase III Trial. J. Clin. Oncol. 10:1992;580-586.
35. Curran W.J., Langer C.J., Keller S.M. et al. Analysis of clinical trials employing pre-operative chemotherapy and/or thoracic radiation therapy for marginally resectable non-small cell lung cancer. Int. J. Rad. Oncol. Biol. Phys. 27:1993;189. abstract.
36. Rosell R., Gómez-Codina J., Camps C. et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 330:1994;153-158.
37. Roth J.A., Atkinson E.N., Fossella F. et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer. 21:1998;1-6.
38. Roth J.A., Fossella F., Komaki R. et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. 86:1994;673-680.
39. Rapp E., Pater J.L., William A. et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: Report of a Canadian multi-center randomized trial. J. Clin. Oncol. 6:1988;633-641.
40. Ruckdeschel J.C., Finkelstein D.M., Ettinger D.S. et al. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer. J. Clin. Oncol. 4:1986;14-22.
41. Elias A.D., Cohen B.F. Dose-intensive therapy in lung cancer. Armitage J.O., Antman K.H. High-Dose Cancer Therapy. 1995;824-846 Williams and Wilkins, Baltimore.
42. Gralla R.J., Casper E.S., Kelsen D.P. et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann. Int. Med. 95:1981;414-420.
43. Klastersky J., Sculier J.P., Ravez P. et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J. Clin. Oncol. 4:1986;1780-1786.
44. Gandara D.R., Crowley J., Livingston R.B. et al. Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: A phase III study of the Southwest Oncology Group. J. Clin. Oncol. 11(5):1993;873-878.
45. 2) in stage IIIA (N2) non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 452:1998.
46. Gomm S.A., Thatcher N., Cuthbert A. et al. High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study. Br. J. Cancer. 63:1991;293-297.
47. Lazarus H.M., Spitzer T.R., Creger R.J. Phase I trial of high-dose etoposide, high-dose cisplatin, and reinfusion of autologous bone marrow for lung cancer. Am. J. Clin. Oncol. 13(2):1990;107-112.
48. Williams S.F., Bitran J.D., Hoffman P.C. et al. High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer. Cancer. 63:1989;238-242.
49. Shea T., Graham M., Bernard S. et al. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. Semin. Oncol. 22(5):1995;80-85.